February 2021 – Page 4 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2021-02-07

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will perform an accelerated assessment of the Marketing Authorisation Application (MAA) for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel). Accelerated assessment is

No Comments InCAR-T

PIER MARIA FORNASARI
2021-02-07

A new study confirms the CDC prediction that B.1.1.7 UK variant will dominate US Covid-19 cases by March.

A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study. Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

Open letter: Support data sharing for COVID-19 in European COVID-19 Data Portal

We need open data, especially open SARS-CoV-2 sequence data, and open science to beat COVID-19 and to prepare for future outbreaks. Why open data is so important When responding to a health crisis, data play a critical role in understanding transmission, infection and symptoms, and in identifying drug targets, developing vaccines and designing public health

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

A not peer reviewed paper by London School of Hygiene finds a 35% increase of dying risk linked to the B.1.1.7 COVID-19 UK variant.

Since B.1.1.7 was first identified in September in southern England, it has become the dominant variant in the United Kingdom and has spread to more than 30 countries. To investigate whether the lineage causes an increased risk of dying, Nicholas Davies, an epidemiologist at the LSHTM, and colleagues analysed data from more than 850,000 people

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

Monoclonal Antibodies for Covid-19: an update

There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized patients but few for patients who are not sick enough to be hospitalized. Monoclonal antibodies are a new treatment for outpatients with COVID-19 who are at risk of progression to severe disease. What Is a Monoclonal Antibody? An antibody is a protein that is naturally

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-07

FDA narrows convalescent plasma Emergency Use Authorization

The US Food and Drug Administration (FDA) revised its emergency use authorization (EUA) for COVID-19 convalescent plasma to limit its use to high titer units and only in hospitalized patients who are in the early stages of the disease or who have impaired humoral immunity. Convalescent plasma emerged as a potential treatment for COVID-19 in the

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

Computers can determine which could be COVID-19 patients clinical evolution

Using patient data, artificial intelligence can make a 90 percent accurate assessment of whether a person will die from COVID-19 or not, according to new research at the University of Copenhagen. Body mass index (BMI), gender and high blood pressure are among the most heavily weighted factors. The research can be used to predict the

No Comments InCovid-19 DIGITAL HEALTH

PIER MARIA FORNASARI
2021-02-06

Investigating the modulation of the COVID-19 immune response

In a recent paper, the research team around Prof. Antonio del Sol from the University’s Luxembourg Centre for Systems Biomedicine (LCSB) describes a new method of how molecules can be identified that amplify and maintain the inflammatory response upon an infection. They use their novel method to identify these molecules in COVID-19 patients and suggest new

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-06

SARS-CoV-2 vaccines: how to communicate the current situation

How do vaccines work? Germs are all around us, both in our environment and in our bodies. When a person is susceptible and they encounter a harmful organism, it can lead to disease and death. The body has many ways of defending itself against pathogens (disease-causing organisms). Skin, mucus, and cilia (microscopic hairs that move debris away

No Comments InCovid-19

PIER MARIA FORNASARI
2021-02-05

SARS-CoV-2 directly infects human erythroid progenitors: implications for emerging erythropoiesis in severe COVID19 patients.

The COVID-19 pandemic continues to constitute a huge threat to public health worldwide and despite the efforts and advances to untangle the mechanisms of SARS-CoV-2 infection and transmission among humans, we are still blind to the overall COVID-19 pathology and its consequences. The results presented in this paper might help understand the emergent erythropoiesis and

No Comments InCovid-19

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Archives: 2021-02-07

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) Accepted for Accelerated Assessment in Europe for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

A new study confirms the CDC prediction that B.1.1.7 UK variant will dominate US Covid-19 cases by March.

A not peer reviewed paper by London School of Hygiene finds a 35% increase of dying risk linked to the B.1.1.7 COVID-19 UK variant.

Monoclonal Antibodies for Covid-19: an update

FDA narrows convalescent plasma Emergency Use Authorization

Computers can determine which could be COVID-19 patients clinical evolution

Investigating the modulation of the COVID-19 immune response

SARS-CoV-2 vaccines: how to communicate the current situation

SARS-CoV-2 directly infects human erythroid progenitors: implications for emerging erythropoiesis in severe COVID19 patients.